CeMIA

CeMIA is a Greece-based biotechnology company focused on molecular and cellular immunobiology services rather than therapeutic drug development. Founded in 2011 in Larissa, it provides sequencing and molecular biology services to laboratories, universities, hospitals, scientific institutions, and health professionals in Greece and the Balkans/Southeast Europe. Its commercial offerings include Next Generation Sequencing, Sanger sequencing, PCR/Real Time PCR applications, fragment analysis, HLA typing, microbiome-related work, and custom molecular biology project support. The company also participates in national and EU research programs as an SME or subcontracting laboratory. CeMIA appears to operate as an active private service provider with accredited histocompatibility testing capabilities and ISO-certified quality systems.